ROBIN HOWARD W

ROBIN HOWARD W, President & CEO, has demonstrated a consistent pattern of selling activity in NKTR (Nektar Therapeutics) shares, as evidenced by SEC Form 4 filings. Over the course of 30 transactions, Howard has exclusively sold shares, with no recorded purchases. The total sell value amounts to $1,210,325.28, reflecting a significant divestment of holdings. Notably, 19 of these sales occurred in recent years, with transactions ranging from $15,549.36 on May 19, 2025, to $125,122.48 on September 5, 2025. The most substantial sales were concentrated in September 2025, with multiple transactions exceeding $50,000, including a $119,795.96 sale on November 25, 2025, and a $102,388.44 transaction on September 9, 2025. Howard’s activity is characterized by a steady liquidation of NKTR shares, with no indication of acquisition or retention. The filings include several awards (denoted by code "A") with no associated value, suggesting equity grants or similar compensation events, but these do not offset the consistent selling trend. The transactions span multiple years, with notable activity in late 2024 and throughout 2025, indicating a prolonged reduction in Howard’s stake in the company. This pattern aligns with a clear bias toward divestment, though the filings provide no context for the motivations behind these sales. The data underscores Howard’s ongoing reduction in NKTR holdings, reflecting a significant shift in personal equity exposure over time.